Fenofibrate Drug Asset Due Diligence Report 2026

This Fenofibrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

272

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fenofibrate can convert its Small molecule drug profile and PPARα biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fenofibrate (query alias: fenofibrate)
Modality / target	Small molecule drug; PPARα; PPARα agonists
Highest global status	Approved
Originator	Fournier Pharma SA
Active developers	Viatris Healthcare GK, Laboratoires Fournier SAS, Mylan Pharmaceuticals, Inc.

The MCP disease footprint includes Primary hypercholesterolemia, Hyperlipidemias, Dyslipidemias. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07296458	Phase 3	Recruiting	132	Percentage of Participants with Normal ALP level
NCT07572552	Phase 2	Not yet recruiting	66	change in the measured biological markers (TNF-α, MDA, and IL-10)
CTR20261665	Not Applicable	进行中（尚未招募）	86	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Therapeutic Modulation of <scp>IL</scp> ‐6/ <scp>STAT</scp> ‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study

Phase 2; n=60; evaluation: Positive. Reported fields: CRp: P-Value = 0.034; CRp: P-Value = 0.034

A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes

Phase 4; n=1151; evaluation: not stated. Reported fields: Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment = 131 Participants ; Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment: Hazard Ratio (HR) = 0.73(95% CI, 0.58 - 0.91), P-Value = 0.006; Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment: Hazard Ratio (HR) = 0.73(95% CI, 0.58 - 0.91), P-Value = 0.006

Design, recruitment and baseline characteristics of the <scp>LENS</scp> trial

Phase 4; n=1151; evaluation: Positive. Reported fields: Female = 27 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fenofibrate addresses Primary hypercholesterolemia, Hyperlipidemias, Dyslipidemias. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-01-02	Handok Begins Domestic Sales of Hyperlipidemia Treatment Lipidil from Korea Abbott	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Fixed dose combinations of integrin inhibitor with PPAR agonists”. The milestone feed surfaced a patent-application signal described as “Combination of an FGFR4 inhibitor with a PPAR agonist”. The milestone feed surfaced a patent-application signal described as “Synthesis method of fenofibrate impurity”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO